Leerink Partnrs Issues Positive Estimate for VRTX Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Leerink Partnrs upped their Q2 2025 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a research report issued on Tuesday, May 6th. Leerink Partnrs analyst D. Risinger now expects that the pharmaceutical company will earn $3.78 per share for the quarter, up from their previous forecast of $3.58. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. Leerink Partnrs also issued estimates for Vertex Pharmaceuticals’ Q3 2025 earnings at $4.28 EPS, Q4 2025 earnings at $4.70 EPS, FY2025 earnings at $16.24 EPS and FY2026 earnings at $17.60 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same period in the previous year, the company earned $4.76 earnings per share. The company’s quarterly revenue was up 2.6% compared to the same quarter last year.

VRTX has been the topic of several other research reports. Wolfe Research downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a research note on Wednesday. BMO Capital Markets set a $545.00 price objective on Vertex Pharmaceuticals in a research note on Friday, January 31st. Piper Sandler lowered their target price on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. HC Wainwright reissued a “buy” rating and set a $550.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Finally, Scotiabank dropped their target price on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating for the company in a research note on Tuesday. Thirteen research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $515.04.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock opened at $425.30 on Friday. The company has a market capitalization of $109.34 billion, a P/E ratio of -193.32, a P/E/G ratio of 2.11 and a beta of 0.51. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88. The stock has a 50 day moving average of $488.74 and a two-hundred day moving average of $465.90.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VRTX. Quent Capital LLC raised its position in shares of Vertex Pharmaceuticals by 4.5% during the 1st quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company’s stock worth $249,000 after purchasing an additional 22 shares during the last quarter. Truvestments Capital LLC increased its position in Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock worth $40,000 after buying an additional 23 shares in the last quarter. Advisor OS LLC raised its holdings in shares of Vertex Pharmaceuticals by 4.4% in the first quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock worth $263,000 after acquiring an additional 23 shares during the last quarter. Simon Quick Advisors LLC lifted its position in shares of Vertex Pharmaceuticals by 1.1% in the fourth quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company’s stock valued at $900,000 after acquiring an additional 24 shares in the last quarter. Finally, Spinnaker Trust boosted its stake in shares of Vertex Pharmaceuticals by 2.1% during the fourth quarter. Spinnaker Trust now owns 1,235 shares of the pharmaceutical company’s stock valued at $497,000 after acquiring an additional 25 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Ourania Tatsis sold 530 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the transaction, the executive vice president now directly owns 58,539 shares of the company’s stock, valued at approximately $27,825,928.26. This represents a 0.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,315 shares of company stock valued at $2,121,012 in the last quarter. 0.20% of the stock is currently owned by insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.